Cargando…
The Role of Immunotherapy in Multiple Myeloma
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards...
Autores principales: | Kocoglu, Mehmet, Badros, Ashraf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812367/ https://www.ncbi.nlm.nih.gov/pubmed/26784207 http://dx.doi.org/10.3390/ph9010003 |
Ejemplares similares
-
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era
por: Rybinski, Brad, et al.
Publicado: (2022) -
Therapy-related B-lymphoblastic leukemia after multiple myeloma
por: Kallen, Michael E., et al.
Publicado: (2022) -
Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study
por: Rybinski, Brad, et al.
Publicado: (2021) -
Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019) -
Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)